Brief: HCW Biologics Shows Paper On Potential Of Cancer Immunotherapeutic
24/08/2021 13:29
Aug 24 (Reuters) - HCW Biologics Inc HCWB.O :
* HCW BIOLOGICS SHOWCASES SCIENTIFIC PAPER IN MOLECULAR
THERAPY
HIGHLIGHTING POTENTIAL OF HCW9218 AS NOVEL, BIFUNCTIONAL CANCER
IMMUNOTHERAPEUTIC
* HCW BIOLOGICS - INVESTIGATIONAL NEW DRUG APPLICATION FOR
CHEMOTHERAPY-REFRACTORY PANCREATIC CANCER EXPECTED TO BE FILED
BY YEAR-END 2021
Source text for Eikon: ID:nGNXccJMCX
Further company coverage: HCWB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM